From clinical trials to clinical practice: Upcoming drug developments in multiple myeloma

Paul Richardson

At the 20th Congress of the European Hematology Association (EHA), Paul Richardson, MD, of Dana-Farber Cancer Institute, Boston, MA, highlights new approaches under evaluation for the management of patients with multiple myeloma that may be introduced in the clinic in the upcoming years. These agents include the monoclonal antibodies, daratumumab and elotuzumab.

Subject:

Multiple Myeloma

Medicines:

Daratumumab, Elotuzumab, Lenalidomide

Event:

EHA 2015

Recorded:

12th June 2015